ReviewImmunoTargets and therapy2018
Oncogenes in immune cells as potential therapeutic targets.
Review in ImmunoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Oxidative Stress, Genetic Factors and Behavioral Responses to Chemical Exposure: Insights into Cancer Development in Zebrafish (Danio Rerio).Biochemical genetics · 2026Review
- Oncolytic Virus Therapy in a New Era of Immunotherapy, Enhanced by Combination with Existing Anticancer Therapies: Turn up the Heat!Journal of Cancer · 2025Review
- Is Silver a Precious Metal for G-Quadruplex Stabilization Mediated by Porphyrins?International journal of molecular sciences · 2024Article
- Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications.Frontiers in immunology · 2023Review
- High-Grade Cervical Intraepithelial Neoplasia (CIN) Associates with Increased Proliferation and Attenuated Immune Signaling.International journal of molecular sciences · 2021Article
- 5-aza-2'-deoxycitidine inhibits cell proliferation, extracellular matrix formation and Wnt/β-catenin pathway in human uterine leiomyomas.Reproductive biology and endocrinology : RB&E · 2021Article
- Notch signaling defects in NK cells in patients with cancer.Cancer immunology, immunotherapy : CII · 2021Article
- CTLA-4 in Regulatory T Cells for Cancer Immunotherapy.Cancers · 2021Review
- Resistance to Immunotherapy: Mechanisms and Means for Overcoming.Advances in experimental medicine and biology · 2021Article
- Understanding the Role of Innate Immune Cells and Identifying Genes in Breast Cancer Microenvironment.Cancers · 2020Review
- Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy.Virchows Archiv : an international journal of pathology · 2019Review
- Abnormal Expression of c-Myc Oncogene in NK Cells in Patients with Cancer.International journal of molecular sciences · 2019Article
- Transcriptome analysis to identify the Ras and Rap1 signal pathway genes involved in the response of TM3 Leydig cells exposed to zearalenone.Environmental science and pollution research international · 2018Article
- Deciphering the Epigenetic Symphony of Cancer: Insights and Epigenetic Therapies Implications.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of deregulated expression of oncogenes and tumor-suppressor genes in tumor development has been intensively investigated for decades. However, expression of oncogenes and their potential role in immune cell defects during carcinogenesis and tumor progression have not been thoroughly assessed. The defects in proto-oncogenes have been well documented and evaluated mostly in tumor cells, despite the fact that proto-oncogenes are expressed in all cells, including cells of the immune system. In this review, key studies from immune-mediated diseases that may be associated with oncogene signaling pathways are refocused to provide groundwork for beginning to understand the effects of oncogenes in and on the cancer-related immune system dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.